The boardroom question in pharma has changed. It used to be, should we invest in AI? That debate is settled. McKinsey estimates generative AI alone could unlock between $60 billion and $110 billion in annual value for the pharmaceutical sector. The potential has never been in doubt. 

What is under scrutiny now is far more consequential: how do you actually capture it? As of 2026, pharma organizations are asking how to scale AI responsibly, integrate it securely, and generate measurable ROI across workflows. And sitting at the center of all three is one decision that does not get nearly enough rigorous attention: Do you build AI capability in-house? Buy an existing solution off the shelf?  

Three paths. Vastly different cost, timeline, and risk profiles. And in an industry where a wrong technology call can cost years and hundreds of millions of dollars, the stakes of choosing incorrectly are unlike almost any other sector. 

The data makes the urgency plain. Only 11% of pharma organizations have achieved enterprise-wide AI implementation despite widespread adoption efforts. Most are stuck in pilot purgatory, having proven the concept without finding a path to scale. McKinsey's own research shows only around one-third of organizations manage to deploy AI broadly for real impact. The majority test, iterate, report early wins, and then stall. 

The bottleneck is the decision framework around AI implementation. 

Why the old playbook no longer works 

The pharmaceutical industry has moved past the inflated expectations and early disillusionment that characterized 2024 and 2025. This year is being defined by something more demanding: a shift from incremental pilots to system-level change. You are choosing an architecture for the next decade. 

Progress with scaling AI hits the same wall repeatedly across the industry. Most enterprise tech stacks and data ecosystems were not built for it. Persistent gaps in data quality, access, and ownership continue to slow momentum. On the other hand, the volume of data generated in the pharma industry is exploding. In 2012, a Phase III trial collected around 900,000 data points. In 2025, that number is roughly 6 million. Source: Pharmaceutical Executives. 

Traditional systems were simply not designed to manage that volume. Layering AI on top without addressing what sits underneath it is how most organizations end up back at square one. 

The organizations making progress are those embedding AI into existing deterministic, rule-based workflows rather than building it as a separate system. 

That is the context for the build-buy-partner decision. Not a clean whiteboard exercise in strategic optionality, but a live call made against a backdrop of legacy infrastructure, tightening regulatory requirements, and a talent market that cannot keep pace with demand. 

Building in-house: The control premium 

Building means developing AI capability from scratch. You own the models, you own the infrastructure, and you retain full control over your data and intellectual property. 

The appeal is real. Complete ownership. Solutions engineered to your exact workflows. No dependency on a vendor's roadmap or pricing decisions. For capabilities that are genuinely central to your competitive position, such as proprietary patient data models, novel drug discovery pipelines, or IP-sensitive research functions, the argument for building is often the right one. 

But the honest accounting rarely happens upfront. Building is slow, at least 12 months before meaningful output, expensive at the infrastructure level, and deeply dependent on talent that the industry does not have nearly enough of. 

The cost of building is not just infrastructure. It is finding, developing, and retaining people who sit at the intersection of AI capability and pharmaceutical domain expertise. That combination is genuinely rare, and every other sector is competing for the same profiles. 

Build when the capability you are developing is a structural, irreplaceable source of competitive advantage. Not by default. Not because it feels more controlled. And never without a credible plan for sustaining the talent required to run it. 

Buying off the shelf: The speed trap 

Purchasing an existing AI tool offers the fastest route to value on paper. Lower upfront cost, faster deployment, access to tools already tested across similar use cases. 

In practice, it rarely works that cleanly. 

Off the shelf does not mean ready to deploy. Most AI tools require significant customization to align with your compliance requirements, and your strategic roadmap becomes permanently linked to a vendor's priorities, which rarely align perfectly with yours.  

More than a third of AI-related data breaches now cost over $1 million. In pharma, where clinical and patient data fall under GDPR and HIPAA standards, buying a tool your compliance and IT teams had no hand in selecting is a compliance risk. 

There is also the obsolescence problem. The pace of technological evolution in AI means that companies buying static solutions today face the prospect of either continuously upgrading those tools or falling behind. Dependency on vendor update cycles is a strategic constraint most organizations underestimate at purchase time. 

Buy for non-differentiating capabilities where speed genuinely matters and compliance exposure is manageable. The mistake is defaulting to buy because it looks cheaper in a budget presentation, without accounting for customization costs, integration friction, and the internal expertise required to extract value from the tool over time. 

Partnering: Why this is becoming the model of choice 

The model gaining the most traction in 2026 is neither pure build nor pure buy. It is strategic partnership, where your organization contributes domain expertise and proprietary data, and a technology partner brings AI capability, implementation experience, and the organizational infrastructure to scale. 

The distinction matters when evaluating whether partnership is right for your organization. A strategic technology partner embeds AI into your workflows and understands your compliance requirements. They build solutions that function within the systems your teams already use, whether that is your ERP, your document management platform, your pharmacovigilance stack, or your supply chain infrastructure. 

Collaborating with an experienced implementation partner consistently produces faster time to value compared to in-house development, while preserving data ownership and strategic control. The partnership model also addresses the talent gap more elegantly than any alternative. Rather than hiring AI talent you may not be able to retain, you access implementation expertise while your internal teams hold strategic ownership of the outcomes. 

This is precisely why Saxon built AIssist, as an enterprise AI platform rather than a point solution. The premise is that pharma and life sciences organizations need AI that works within their existing workflows and governance frameworks. That means connecting enterprise search, intelligent assistants, and workflow automation across functions like supply chain, pharmacovigilance, procurement, and HR, all within a secure, governed architecture, without requiring teams to change the tools they already trust. 

The right partner relationship is one where your data stays yours, your compliance posture is never at risk, and the solutions continuously improve over time as they learn from your specific operational context. 

Check your foundation before you choose a path 

Here is what most leaders skip in the push to make a visible decision. 

Before you choose a path, you need to honestly assess whether your organization is ready for any of them. Most pharma AI projects stall during data engineering, not model development. Commercial, clinical, manufacturing, and supply chain data exist in incompatible silos with inconsistent governance. By the time teams wrangle data into usable form, 60% of project timelines have already elapsed. 

The most common reason AI fails in pharma is what is underneath it: messy, inconsistent data with no clear ownership; compliance and IT teams who were never part of the conversation; and AI implementations layered on top of legacy systems without the workflow redesign needed to drive adoption. 

Clean your data first. Not as a prerequisite to the pilot, but as a genuine organizational priority. Assign an internal owner with real authority over AI initiatives. Get compliance and IT in the room before the first vendor conversation, not after the contract is signed. These are not administrative tasks. They are what separates a successful implementation from another paused pilot with a budget hit attached to it. 

The organizations that are pulling ahead in 2026 are not the ones with the most sophisticated models. They are the ones that connected the dots, modernized their data foundations, and deployed AI in ways that embedded trust across the organization rather than creating another layer of complexity on top of existing systems. 

Choose deliberately. The window is narrowing. 

The era of AI pilots is behind us. What is in front of us is consequences, positive for organizations that chose with clarity, and negative for those still running the same experiments with different vendors. 

Build where you have genuine, defensible differentiation to protect. Buy where speed and commodity capability are what the use case actually calls for. Partner where you need to move with urgency without sacrificing data ownership, compliance posture, or long-term strategic control. 

The organizations that will lead the next phase of pharma AI are not the ones that moved fastest or spent most. They are the ones that chose most deliberately, invested in the right foundations, and built capability that compounds over time rather than generating one-time wins that fade as soon as the implementation team leaves. 

Audit what you already have. And choose with the same discipline you would apply to any other irreversible strategic commitment. 

Because that is exactly what this is.